The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS
NCT ID: NCT05451433
Last Updated: 2022-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
52 participants
INTERVENTIONAL
2022-08-01
2022-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT07168434
Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome
NCT01613456
Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome
NCT00543478
The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome
NCT05064930
Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome
NCT02545413
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Group
Get intervention drug Normagut capsule twice a day
Saccharomyces Boulardii 250 MG
Normagut capsule twice a day
Control Group
Get placebo capsule twice a day
Placebo
Placebo capsule twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saccharomyces Boulardii 250 MG
Normagut capsule twice a day
Placebo
Placebo capsule twice a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with IBS based on ROME IV criteria
* agree to be participant by signing inform consent
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fakultas Kedokteran Universitas Indonesia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marcellus Simadibrata, Prof. PhD., SpPD, KGEH
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-03-0280
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.